Abstract
BackgroundTreatment failure after radiotherapy of head and neck squamous cell carcinoma (HNSCC) could be a significant problem. Our objective is to sensitize SCCVII cells to ionizing radiation in vitro and in vivo through inhibiting ATM expression using antisense oligodeoxynucleotides (AS-ODNs), and investigate the potential mechanism of radiosensitization.MethodsWe designed and synthesized AS-ODNs that target ATM mRNA to reduce the ATM expression. The influence on the expression of ATM mRNA and protein in SCCVII cells were analysed by real-time quantitative PCR and western blotting respectively. Clonogenic survival assay was performed to detect the survival ability of SCCVII cells after irradiation, while flow cytometry used to analyse the cell cycle and apoptosis. The volume of solid tumors generated with SCCVII cells was measured, and cell apoptosis was analysed by TUNEL assay after irradiation.ResultsThe relative ATM mRNA and protein expression in SCCVII cells treated with ATM AS-ODNs were decreased to 25.7 ± 3.1% and 24.1 ± 2.8% of that in untreated cells respectively (P < 0.05). After irradiation, the survival fraction (SF) of cells treated with ATM AS-ODNs was lower than that of other groups at the same dose of radiation (P < 0.05), while the percentage of cells in G2/M phase decreased and apoptotic rate of cells increased(P < 0.05). The inhibition rate in SCCVII cells solid tumor exposed to X-ray alone was 23.2 ± 2.7%, while it was 56.1 ± 3.8% in the group which irradiated in combination with the treatment of ATM AS-ODNs (P < 0.05). The apoptotic index for the group irradiated in combination with ATM AS-ODNs injection was 19.6 ± 3.2, which was significantly higher than that of others (P < 0.05)ConclusionInhibition of ATM expression sensitized SCCVII cells to ionizing radiation in vitro and in vivo. The potential mechanism should be the defective G2/M cell cycle checkpoint control and enhanced radiation-induced apoptosis.
Highlights
Treatment failure after radiotherapy of head and neck squamous cell carcinoma (HNSCC) could be a significant problem
We manage to examine whether reduction of ataxia-telangiectasia mutated (ATM) expression after antisense oligodeoxynucleotides (AS-ODNs) treatment would result in enhanced radiosensitivity of p53-mutated SCCVII cells from C3H/He mice through the aberrant G2/M checkpoint
After 48 hours treatment, there were no significant difference among the group treated with liposome alone, the group treated with Sen-ODNs and the group treated with MisODNs
Summary
Treatment failure after radiotherapy of head and neck squamous cell carcinoma (HNSCC) could be a significant problem. Our objective is to sensitize SCCVII cells to ionizing radiation in vitro and in vivo through inhibiting ATM expression using antisense oligodeoxynucleotides (AS-ODNs), and investigate the potential mechanism of radiosensitization. Despite advances in surgical treatments, radiotherapy is superior in its ability to preserve function and appearance in the treatment of head and neck squamous cell carcinoma (HNSCC). In p53 mutated cell lines, disruption of ATM resulted in defective G2/M checkpoint control, radio-resistant DNA synthesis, retarded cell proliferation and enhanced radiosensitivity[15,16]. We manage to examine whether reduction of ATM expression after antisense oligodeoxynucleotides (AS-ODNs) treatment would result in enhanced radiosensitivity of p53-mutated SCCVII cells from C3H/He mice through the aberrant G2/M checkpoint
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Experimental & Clinical Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.